Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens

Hepatology

Volumn 61, Issue 6, 2015, Pages 1793-1797

  Wyles, David ^a   Pockros, Paul ^b   Morelli, Giuseppe ^c   Younes, Ziad ^d   Svarovskaia, Evguenia ^e   Yang, Jenny C ^e   Pang, Phillip S ^e   Zhu, Yanni ^e   McHutchison, John G ^e   Flamm, Steven ^f   Lawitz, Eric ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SCRIPPS CLINIC   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

^d Gastro One   (United States)

^e GILEAD SCIENCES   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON; PLACEBO; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; BIPOLAR DISORDER; CHOLECYSTITIS; CONSTIPATION; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1 INFECTION; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; INFLUENZA; INSOMNIA; IRRITABILITY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; OPEN STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; SINUSITIS; THORAX PAIN; UNITED STATES; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG COMBINATION; GENETICS; HEPATITIS C, CHRONIC; MIDDLE AGED; TREATMENT FAILURE;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; RIBAVIRIN; TREATMENT FAILURE; URIDINE MONOPHOSPHATE;

EID: 84929600780     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27814     Document Type: Article

References (8)

1. Sovaldi (sofosbuvir) tablets. U.S. prescribing information. Foster City, CA: Gilead Sciences; December 2013.
2. Lalezari JP, Nelson DP, Hyland RH, Lin M, Rossi SJ, Symonds WT, et al. Once-daily sofosbuvir plus ribavirin given for 12 or 24 weeks in treatment-naïve patients with HCV infection: the QUANTUM study. J Hepatol 2013;58(Suppl 1):S346.
3. Rodriguez-Torres M, Lawitz E, Kowdley KV, Nelson DR, Dejesus E, McHutchison JG, et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. J Hepatol 2013;58:663-668.
4. Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013;13:401-408.
5. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013;381:2100-2107.
6. Lawitz E, Mangia S, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887.
7. Harvoni (ledipasvir and sofosbuvir) tablets. U.S. prescribing information. Foster City, CA: Gilead Sciences; October 2014. Available at: http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf. Accessed on February 12, 2015.
8. Osinusi A, Kohli A, Marti MM, Nelson A, Zhang X, Meissner EG, et al. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Ann Intern Med 2014;161:634-638.